Green Mountain Antibodies

Executive Summary

Green Mountain Antibodies (GMAb) is a privately held contract research and manufacturing organization (CRO/CMO) specializing in custom antibody development and production. Founded in 1994 and headquartered in Burlington, Vermont, the company offers end-to-end services including monoclonal antibody development, hybridoma generation, recombinant expression, and antibody purification. GMAb serves academic, biotech, and pharmaceutical clients, positioning itself as a reliable partner in the antibody discovery and production space. The company operates in a competitive but growing market for outsourced antibody services, driven by increasing R&D spend in biopharma. As a private entity with no disclosed funding or revenue, GMAb's financial performance is opaque, but its longevity suggests a stable customer base and operational efficiency. Looking ahead, GMAb may benefit from the broader trend of outsourcing antibody development to specialized CROs, though growth is likely modest given the fragmented competitive landscape. The company's ability to expand its service offerings or secure large contracts with pharmaceutical partners could be key growth drivers. However, without recent news or financial data, the near-term outlook is uncertain. The conviction score reflects the company's stable but unexciting position in the antibody services market, with limited visibility into catalysts.

Upcoming Catalysts (preview)

• Q2 2026Major contract with a top pharmaceutical company40% success
• H2 2026Expansion of facility or new service line (e.g., bispecific antibodies)50% success
• TBDStrategic partnership or acquisition by a larger CRO30% success